hero image
Jan D. Hirsch - UC Irvine. Irvine, CA, US

Jan D. Hirsch

Founding Dean, School of Pharmacy and Pharmaceutical Sciences | UC Irvine


Jan Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research.





loading image


Drug Development & Product Management I Jan D. Hirsch I Williams Ettouati I UC San Diego UCI Pharmaceutical Sciences Planned School of Pharmacy & Pharmaceutical Sciences Information Session: MS in Drug Development & Product Management I Jan D. Hirsch I Williams Ettouati




Dr. Jan D. Hirsch is Founding Dean of the University of California Irvine School of Pharmacy and Pharmaceutical Sciences and also Professor of Clinical Pharmacy. She is a Distinguished Scholar and Fellow of the National Academies of Practice (NAP) in Pharmacy, and Distinguished Fellow of the Get the Medications Right (GTMRx) Institute, and joined UC Irvine in January of 2019.
Previously she was Professor of Clinical Pharmacy and Chair of the Division of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego. She was also Executive Director of an outreach program of the school providing medication therapy management services in the community. She received her B.S. in Pharmacy and M.S. and Ph.D. degrees in Pharmacy Administration from the University of South Carolina, College of Pharmacy. Prior to returning to academia, she spent 14 years in the pharmaceutical and managed care industries where she was responsible for establishing and managing outcomes research departments for two pharmaceutical companies (Glaxo Group Research in Greenford (UK) and Allergan (US)) and a pharmacy benefit management company (Prescription Solutions (US)).

Dr. Hirsch's research interests are focused in the areas of pharmacoeconomics and outcomes research. Specifically, i) assessing the full value (economic, clinical and humanistic) of pharmacy services and pharmaceuticals and ii) integrating patient reported outcomes (PRO's) [e.g. Health Related Quality of Life (HRQOL)] into pharmaceutical and medical practice to improve patient management.

She has served as PI or Co-PI for many studies evaluating the clinical, economic and humanistic outcomes for patients receiving novel pharmacy services for diabetes, hypertension, mental health, and HIV/AIDS. This research has been recognized by state and federal agencies, professional pharmacy organizations and the interdisciplinary National Academies of Practice. Dr. Hirsch has also been the PI for studies creating and/or validating four HRQOL instruments [Functional Living Index Emesis (FLIE), Ocular Surface Disease Index (OSDI), Gout Impact Scale (GIS), Heart Transplant Treatment Burden Questionnaire (HTBQ)] and a method for measuring medication regimen complexity (MRCI). Each of these has been an important contribution to clinical practice and research as evidenced by their uptake by other researchers and inclusion in more than 100 clinical trials.

Areas of Expertise (9)

Comprehensive Medication Management (CMM)

Medication Therapy Management

Clinical Pharmacy


Drug Development

Gout Impact Scale

Pharmaeutical Services

Disease-specific Instruments

Health Related Quality of Life

Accomplishments (4)

Distinguished Scholar and Fellow National Academies of Practice in Pharmacy (NAP) (professional)

2018 Distinguished Scholar and Fellows have an exemplary career of ten years or more, and are committed to interprofessional practice and accessible, affordable healthcare for all. Fellows are judged by distinguished peers to have made significant and ongoing contributions in their profession. Distinguished Scholar and Fellows have made notable academic achievements such as significant and enduring educational and/or research contribution to practice.

Distinguished Fellow of Get the Medications Right Institute (GTMRx) (professional)

2019 The GTMRx Distinguished Fellows program celebrates the exceptional contributions of those advancing our ability to enhance life by ensuring appropriate and personalized use of medication and gene therapies. Distinguished Fellows drive innovation, policy, and work alongside like-minded national leaders to advance evidence, best practices, and ideas to accelerate the transformation to a team-based, person-centered approach to comprehensive medication management.

Excellence in Teaching Award (professional)

2004 UCSD

Distinguished Alumni Award (professional)

2002 University of South Carolina College of Pharmacy

Education (3)

University of South Carolina: MS, Pharmacy Administration 1982

University of South Carolina: Ph.D., Pharmacy Administration 1986

University of South Carolina: BS, Pharmacy 1980

Affiliations (7)

  • American Pharmaceutical Association (APhA)
  • Academy of Managed Care Pharmacy (AMCP)
  • American Association of Colleges of Pharmacy (AACP)
  • California Pharmacists Association (CPhA)
  • National Academies of Practice (NAP)
  • Applied Pharmacoeconomics and Outcomes Research Forum
  • Get the Medications Right (GTMRx) Institute

Languages (1)

  • English

Media Appearances (6)

Should Kids Take Ozempic, Wegovy? The Idea Has Some Experts Worried

HealthDay  online


“Our major concern is the unbalance and inappropriate reductions in calorie or energy intake associated with these weight-loss drugs,” said Dr. Dan Cooper, a professor of pediatrics at UCI School of Medicine. … Co-author Jan Hirsch, [founding] dean of the UCI School of Pharmacy and Pharmaceutical Sciences [and professor of clinical pharmacy], said, … "These drugs administered without proper supervision could cause a minefield of health and emotional problems for children as they age." … “News about GLP-1RA agonists has infiltrated social media outlets …. “ said Dr. Emma Cooper, a resident in the Department of Psychiatry and Human Behavior at UCI School of Medicine.

view more

Pharmacists in Nontraditional Roles Are Not Included in Bureau of Labor Statistics Count of Working Pharmacists

Pharmacy Times  online


Jan Hirsch, BS, PhD, FNAP, UCI founding dean and professor of clinical pharmacy in the School of Pharmacy and Pharmaceutical Sciences write, “Collective action among stakeholders is needed to first produce an inclusive count of pharmacists giving accurate visibility to the magnitude of pharmacists in non-traditional roles, and second to re-examine projections for pharmacist jobs using an inclusive view for all positions that value pharmacy training and expertise. These are essential steps to allow an accurate perception of pharmacy as a career path and meaningful workforce planning that ensures the profession will be prepared with an adequately trained workforce to meet health care needs of the future.”

view more

UC Irvine welcomes inaugural class of pharmacy school with white coat ceremony

Daily Pilot  online


“It’s not just students but our faculty too,” said Jan Hirsch, founding dean of the school, in a call Thursday.

view more

UCI to welcome inaugural Pharm.D. class with white coat ceremony

Drug Store News  online


"We are thrilled to welcome the first cohort of Pharm.D. students, who are the next generation of pharmacists who will help people live healthier, better lives,” said Jan Hirsch, founding dean of UCI’s School of Pharmacy & Pharmaceutical Sciences.

view more

Gaps Feared if Hospitals, Pharmacies Sole Covid Vaccine Source

Bloomberg  online


“As the COVID-19 vaccines start rolling out, pharmacists will be key to the rapid and equitable distribution and administration of doses, just as they have been with COVID-19 testing,” said Jan D. Hirsch, founding dean of the UCI’s School of Pharmacy & Pharmaceutical Sciences, said in a statement.

view more

New faculty faces

UCI News  online


Jan Hirsch, director and founding dean of UCI’s planned School of Pharmacy & Pharmaceutical Sciences, who is an acclaimed researcher, pharmacist and organizational leader with experience in bridging academics, scholarship and clinical practice in the private and public sectors;

view more

Preferred Pronouns (1)

Preferred Pronouns

She, Her, Hers

Research Focus (2)

Gout disease-specific quality of life and the association with gout characteristics


Assess the association of gout characteristics with health-related quality of life (HRQoL) using a new gout-specific HRQoL instrument, the Gout Impact Scale (GIS).

view more

Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life


The study was conducted to evaluate the reliability and validity of an instrument assessing the influence of gout (acute and chronic) on health-related quality of life (HRQOL).

view more

Research Grants (8)

Assessment of Stakeholder Perspectives of the Clinical Utility of Pharmacogenomics in Solid Organ Transplantation

Skaggs Scholar Program $67,514


The focus of the study is to assess stakeholder perspectives regarding the clinical utility of pharmacogenomic (PGx) testing following kidney, liver, and heart transplantation. The study conducted by individual semi-structured interviews and focus groups with kidney, liver, and heart transplantation patients and providers.

view more

Reducing Hospital Utilization (Readmissions and ED) Community Pharmacist Medication Reconciliation Program

United Healthcare $227,405


A longitudinal study seeking to reduce hospital reutilization (readmission and ER utilization) by adding community pharmacists to the care team. The objective of the study is to conduct and evaluate implementation of a community pharmacy based transitions of care program (PharmD_TOC)for high-risk post-discharge patients. The study runs from September 2016 to January 2021.

view more

Multidimensional Efficacy of Canukinumab vs. Triamcinolone for Gouty Arthritis Treatment

Novartis Pharmaceuticals $50,000


Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, may be a potential therapeutic option for treating acute gout attacks and delaying new attacks in these patients (pts). Efficacy and safety of canakinumab was previously demonstrated in two 12-week, multicenter, double-blind, double dummy, active controlled trials (β-RELIEVED [N=228]; β-RELIEVED II [N=226]).1 Health-related quality of life was also measured in these studies, but not all patients completed each questionnaire. Therefore, a composite health outcomes response endpoint was developed to better interpret each patient’s overall response to treatment.

view more

Medication Regimen Complexity Methods and Measurement in Defined Clinical Populations

Skaggs Scholars Program $88,000


An investigation of medication regimen complexity in four disease areas (hypertension, diabetes, geriatric depression and HIV), and additional measures of medication risk that should also be included in assessing the “complexity” of medication regimens in these patient populations, as a method of identifying patients who may benefit most from pharmacist intervention.

Pilot Project for Medication Therapy Management (MTM) – PharmD/MD Collaborative Practice in Primary Care.

National Institutes of Health (NIH) - National Heart, Lung and Blood (NHLBI - 1RC2HL101811-01) $573,215


A randomized, pragmatic, clinical trial of hypertensive patients randomly selected to receive care from a pharmacist within a PharmD-MD Collaborative Practice team in a university primary care clinic.

A pilot study of a pharmacist-led Medication Therapy Management Services (MTMS) in Mental Health Clinic

California Department of Healthcare Services $52,487


Challenges and opportunities associated with needs assessment, implementation, and reimbursement of a psychiatric pharmacist medication therapy management (MTM) clinic.

Validation of the Gout Assessment Questionnaire (GAQ) in a non-clinical trial population.

TAP Pharmaceuticals $195,867


The objectives of this study were to further the development of a gout-specific quality of life instrument to enhance its use in clinical practice and to evaluate the psychometric properties of the new Gout Assessment Questionnaire (GAQ2.0) in a large community-based population.

Gout Impact (GI of GAQ2.0) Responsiveness and Minimal Important Difference Evaluation

TAP Pharmaceuticals $87,500


A longitudinal study of gout patients investigating the responsiveness and minimal important difference (MID) of the GAQ2.0 to aid interpretation of results when the instrument is used in clinical trials or clinical practice to monitor change in gout status.

Articles (37)

National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation. Clinical Transplantation.


KM Deininger, SM Tsunoda, JD Hirsch, HD Anderson, YM Lee, CK McIlvennan, RL Page, JN Tran, CL Aquilante

2020 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

view more

Local pharmacies can reduce the dual risks of COVID19 and influenza this fall. Now is the time to prepare.

The Hill

JH Watanabe and JD Hirsch

2020 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

PaCIR: A Tool to Enhance Pharmacist Patient Care Intervention Reporting

Journal of the American Pharmacists Association

PG Clay, AL Burns, BJ Isetts, JD Hirsch, MA Kliethermes, LG Planas

2019 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Patterns of Stress, Coping and Health-Related Quality of Life in Doctor of Pharmacy Students

American Journal of Pharmaceutical Education

JD Hirsch, P Nemlekar, P Phuong, KA Hollenbach, KC Lee, DS Adler and CM Morello

2020 To examine perceived stress, coping strategies, and health-related quality of life in Doctor of Pharmacy students across the first three years (pre-clinical portion) of the curriculum.

view more

Improved glycemic control outcomes regardless of mental health disorders in a pharmacist-endocrinologist diabetes intense medical management (DIMM) “tune up” clinic.

Annals of Pharmacotherapy

CM Morello, T Nguyen, L Tao, JD Hirsch

2020 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Advancing Pharmacist Collaborative Care within Academic Health Systems


L Awdishu, R Singh, I Saunders, J Hirsch, S Lorentz, R Atayee, J Ma, S Tsunoda, J Namba, C Mnatzaganian, N Painter, J Watanabe, F Yam, K Lee, C Daniels, C Morello

2019 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Evaluation of a Short, Interactive Diabetes Self-Management Program by Pharmacists for Type 2 Diabetes

BMC Research Notes

RF Singh, P Kelly, A Tam, J Bronner, CM Morello, JD Hirsch

2018 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Federal and Patient Spending on Ten Most Expensive Medications in Medicare Part D from 2011 to 2015

Journal of the American Geriatrics Society

JH Watanabe, JD Hirsch

2018 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management “Tune-Up” Clinic

Journal of Managed Care & Specialty Pharmacy

Hirsch et al

2017 In 2012 U.S. diabetes costs were estimated to be $245 billion, with $176 billion related to direct diabetes treatment and associated complications. Although a few studies have reported positive glycemic and economic benefits for diabetes patients treated under primary care physician (PCP)-pharmacist collaborative practice models, no studies have evaluated the cost-effectiveness of an endocrinologist-pharmacist collaborative practice model treating complex diabetes patients versus usual PCP care for similar patients.

view more

Cost of Prescription Drug-Related Morbidity and Mortality

Annals of Pharmacotherapy

JH Watanabe, T McInnis, JD Hirsch

2018 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Economic Impact of and Treatment Options for Type 2 Diabetes

American Journal of Managed Care

JD Hirsch, CM Morello

2017 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Estimated Cost-Effectiveness, Cost-Benefit, and Risk Reduction Associated with a Pharmacist-Endocrinologist Diabetes Intense Medical Management “Tune Up” Clinic.

Journal of Managed Care and Specialty Pharmacy

JD Hirsch, M Bounthavong, A Arjmand, DR Ha, CL Cadiz, A Zimmerman, H Ourth, AP Morreale, SV Edelman, CM Morello

2017 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Strategies for Addressing the Cost of Nonadherence in Diabetes

American Journal of Managed Care

CM Morello, JD Hirsch

2017 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Student Pharmacists' Perceptions of Immunizations

Currents in Pharmacy Teaching and Learning

K Kubli, S McBane, JD Hirsch, S Lorentz

2017 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Clinical Outcomes Associated With a Collaborative Pharmacist-Endocrinologist Diabetes Intense Medical Management “Tune Up” Clinic in Complex Patients

Annals of Pharmacotherapy

CM Morello, MLD Christopher, L Ortega, J Khoan, T Rotunno, SV Edelman, RR Henry, JD Hirsch

2016 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Primary Care–based, Pharmacist–physician Collaborative Medication-therapy Management of Hypertension: A Randomized, Pragmatic Trial

Clinical Therapeutics

Hirsch et al

2014 A collaborative pharmacist–primary care provider (PharmD-PCP) team approach to medication-therapy management (MTM), with pharmacists initiating and changing medications at separate office visits, holds promise for the cost-effective management of hypertension, but has not been evaluated in many systematic trials. The primary objective of this study was to examine blood pressure (BP) control in hypertensive patients managed by a newly formed PharmD-PCP MTM team versus usual care in a university-based primary care clinic.

view more

Changes in medication regimen complexity and the risk for 90-day hospital readmission and/or emergency department visits in U.S. Veterans with heart failure

Res Social Adm Pharm

FK Yam, T Lew, SA Eraly, WI Hsiang, JD Hirsch, MJ Devor

2016 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Validation of a Patient‐Level Medication Regimen Complexity Index as a Possible Tool to Identify Patients for Medication Therapy Management Intervention


Jan D. Hirsch, Kelli R. Metz, Patrick W Hosokawa, Anne M. Libby et al

2014 The Medication Regimen Complexity Index (MRCI ) is a 65‐item instrument that can be used to quantify medication regimen complexity at the patient level, capturing all prescribed and over‐the‐counter medications. Although the MRCI has been used in several studies, the narrow scope of the initial validation limits application at a population or clinical practice level.

view more

A Composite Endpoint Measure to Consolidate Multidimensional Impact of Treatment on Gouty Arthritis

Open Journal of Rheumatology and Autoimmune Diseases

AJ Sarkin, A Gnanasakthy, RS Lale, KJ Choi, JD Hirsch

2013 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis‐related health outcomes measures

International Journal of Clinical Practice

JD Hirsch, A Gnanasakthy, R Lale, K Choi, AJ Sarkin

2014 Canakinumab (CAN ), a selective, fully human, anti‐IL ‐1β monoclonal antibody, has demonstrated long‐term benefits in gouty arthritis (GA ) patients, who have contraindications for, or are unresponsive or intolerant of, non‐steroidal anti‐inflammatory drugs (NSAID s) or colchicine (two trials:β‐RELIEVED [n = 228]; β‐RELIEVED II [n = 226]). The trials collected different responses, including patient‐reported outcomes (PRO ). A composite response end‐point (CRE ) was used to interpret each patient's overall response to treatment.

view more

Navigating complex patients using an innovative tool: The MTM Spider Web

Journal of American Pharmacists Association

CM Morello, JD Hirsch, KC Lee.

2013 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Patient-level medication regimen complexity in older adults with depression

Clinical Therapeutics

SA Linnebur, JP Vande Griend, KR Metz, PW Hosokawa, JD Hirsch, AM Libby

2014 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Development of a Pharmacist-Psychiatrist Collaborative Medication Therapy Management (MTM) Clinic

Journal of the American Pharmacists Association

KB Tallian, JD Hirsch, GM Kuo, C Chang, T Gilmer, M Messinger, P Chan, CE Daniels, KC Lee

2012 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Documenting and Describing the Value of Medication Therapy Management Services (MTMS) and Outcomes in Community Pharmacy: Methods and Case Study

California Pharmacist

JD Hirsch, KC Lee, CM Morello

2011 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Patient-Level Medication Regimen Complexity Across Populations with Chronic Disease

Clinical Therapeutics

AM Libby, DN Fish, PW Hosokawa, SA Linnebur, KR Metz, KV Nair, JJ Saseen, JP Vande Griend, SP Vu, JD Hirsch

2013 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Antiretroviral Therapy Adherence, Medication Use, and Health Care Costs During 3 Years of a Community Pharmacy Medication Therapy Management Program for Medi-Cal Beneficiaries with HIV/AIDS

Journal of Managed Care Pharmacy

J D Hirsch, M Gonzales, A Rosenquist, TA Miller, TP Gilmer, BM Best

2011 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Minimally Important Differences of the Gout Impact Scale in a Randomized Controlled Trial

Rheumatology (Oxford)

D Khanna, AJ Sarkin, MM Shieh, AF Kavanaugh, RA Terkeltaub, SJ Lee, JA Singh, JD Hirsch

2011 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Health Care Utilization in Patients with Gout.

Seminars in Arthritis and Rheumatism

JA Singh, A Sarkin , M Shieh, D Khanna, R Terkeltaub, SJ Lee, A Kavanaugh, JD Hirsch

2011 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Impact of Gout on Health Related Quality of Life and the Relationship to Gout Characteristics

Patient Related Outcome Measures

JD Hirsch, R Terkeltaub, D Khanna, J Singh, A Sarkin, M Shieh, A Kavanaugh, SJ Lee

2010 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Medication Therapy Management Services in Community Pharmacy: A Pilot Program in HIV Specialty Pharmacies

Journal of Evaluation in Clinical Practice

A Rosenquist, BM Best, TA Miller, TP Gilmer, JD Hirsch

2010 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Pharmacists as Immunizers: A California Survey

California Pharmacist

J Fontanesi, JD Hirsch, S Lorentz, J Rybar

2009 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Predictors of Doctor-Rated and Patient-Rated Gout Severity: Gout Impact Scales Improve Assessment

Journal of Evaluation in Clinical Practice

AJ Sarkin, AE Levack, MM Sheih, AF Kavanaugh, D Khanna, JA Singh, RA Terkeltaub, SJ Lee, JD Hirsch

2010 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Comparison of Pharmacists and Primary Care Providers as Immunizers

The American Journal of Pharmacy Benefits

J Fontanesi, JD Hirsch, Lorentz S, Rybar, D Bowers, J Shafrin

2009 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Students’ Health-Related Quality of Life Across the Preclinical Pharmacy Curriculum

American Journal of Pharmaceutical Education

JD Hirsch, AH Do, AS Manoguerra, D Adler

2009 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Evaluation of an Instrument Assessing Gout Impact on Health-Related Quality of Life

Journal of Rheumatology

JD Hirsch, SJ Lee, R Terkeltaub, D Khanna, J Singh, A Sarkin, J Harvey, A Kavanaugh

2008 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries

Journal of Managed Care Pharmacy

JD Hirsch, A Rosenquist, BM Best, TA Miller, TP Gilmer

2009 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf

Patient request for pharmacist counseling and satisfaction: Automated prescription delivery system vs. regular pick-up counter

Journal of the American Pharmacists Association

JD Hirsch, A Oen, S Robertson, N Nguyen, C Daniels

2009 https://media-speakerfile-pre.s3.amazonaws.com/documents/e63a2ee611561a5c7d8d0122405801fe1602693325.pdf